Optimizing technology for cervical cancer screening in high-resource settings

Expert Review of Obstetrics and Gynecology

Volumn 6, Issue 3, 2011, Pages 343-353

  Richardson, Lyndsay A ^a   Tota, Joseph ^a   Franco, Eduardo L ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

cervical cancer; human papillomavirus; human papillomavirus vaccine; mass screening; Papanicolaou test; test performance

Indexed keywords

MOLECULAR MARKER; VIRUS DNA; WART VIRUS VACCINE;

ALGORITHM; CANCER SCREENING; CYTOLOGY; DNA DETERMINATION; GENE EXPRESSION; GENETIC MARKER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION PREVENTION; INFORMATION PROCESSING; MASS SCREENING; MEDICAL TECHNOLOGY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PREVALENCE; PROCESS OPTIMIZATION; REVIEW; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; VACCINATION;

EID: 79959199006     PISSN: 17474108     EISSN: 17474116     Source Type: Journal    
DOI: 10.1586/eog.11.13     Document Type: Review

References (111)

1. Kitchener HC, Castle PE, Cox JT. Chapter 7: achievements and limitations of cervical cytology screening. Vaccine 24(Suppl. 3), 63-70 (2006)
2. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 24(Suppl. 3), 11-25 (2006)
3. McDougall JA, Madeleine MM, Daling JR, Li CI. Racial and ethnic disparities in cervical cancer incidence rates in the United States, 1992-2003 Cancer Causes Control 18(10), 1175-1186 (2007) (Pubitemid 47498166)
4. Scarinci IC, Garcia FA, Kobetz E et al. Cervical cancer prevention: new tools and old barriers. Cancer 116(11), 2531-2542 (2010)
5. Nanda K, McCrory DC, Myers ER et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann. Intern. Med. 132(10), 810-819 (2000) (Pubitemid 30317797)
6. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 109: Cervical cytology screening. Obstet. Gynecol. 114(6), 1409-1420 (2009)
7. Murphy KJ, Howlett R. Canadian Consensus Guidelines on Human Papillomavirus: Chapter 5: Screening for cervical cancer. J. Obstet. Gynaecol. Can. 29(8), S27-S36 (2007)
8. Arbyn M, Anttila A, Jordan J et al. European guidelines for quality assurance in cervical cancer screening. Second edition - summary document. Ann. Oncol. 21(3), 448-458 (2010)
9. Herzog TJ, Monk BJ. Reducing the burden of glandular carcinomas of the uterine cervix. Am. J. Obstet. Gynecol. 197(6), 566-571 (2007) (Pubitemid 350166265)
10. National Institute for Clinical Excellence (NICE)Guidance on the use of liquid-based cytology for cervical screening (NICE), London, UK (2003)
11. Ronco G, Cuzick J, Pierotti P et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ 335(7609), 28 (2007)
12. Kuhn L, Wang C, Tsai WY, Wright TC, Denny L. Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women. AIDS 24(16), 2553-2561 (2010).
13. Denny L, Kuhn L, Hu CC, Tsai WY, Wright TC Jr. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J. Natl Cancer Inst. 102(20), 1557-1567 (2010)
14. Herrero R, Ferreccio C, Salmeron J et al. New approaches to cervical cancer screening in Latin America and the Caribbean. Vaccine 26(Suppl. 11), L49-L58 (2008)
15. Tsu VD, Pollack AE. Preventing cervical cancer in low-resource settings: how far have we come and what does the future hold? Int. J. Gynaecol. Obstet. 89(Suppl. 2), S55-S59 (2005) (Pubitemid 40488759)
16. Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S. A critical assessment of screening methods for cervical neoplasia. Int. J. Gynaecol. Obstet. 89(Suppl. 2), S4-S12 (2005) (Pubitemid 40488754)
17. Mahe C, Gaffikin L. Screening test accuracy studies: how valid are our conclusions? Application to visual inspection methods for cervical screening. Cancer Causes Control 16(6), 657-666 (2005) (Pubitemid 41110956)
18. Blumenthal PD, Lauterbach M, Sellors JW, Sankaranarayanan R. Training for cervical cancer prevention programs in low-resource settings: focus on visual inspection with acetic acid and cryotherapy. Int. J. Gynaecol. Obstet. 89(Suppl. 2), S30-S37 (2005)
19. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189(1), 12-19 (1999) (Pubitemid 29406813)
20. Cuzick J, Arbyn M, Sankaranarayanan R et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26(Suppl. 10), K29-K41 (2008)
21. Stuart G, Taylor G, Bancej CM et al. Report of the 2003 pan-Canadian forum on cervical cancer prevention and control. J. Obstet. Gynaecol. Can. 26(11), 1004-1028 (2004)
22. Stuart G, Taylor G. Report of the 2003 pan-Canadian forum on cervical cancer prevention and control. J. Obstet. Gynaecol. Can. 26(11), 1004-1028 (2004)
23. Solomon D, Davey D, Kurman R et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287(16), 2114-2119 (2002) (Pubitemid 34437346)
24. ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of lowγrade squamous intraepithelial lesion cytology interpretations. Am. J. Obstet. Gynecol. 188(6), 1393-1400 (2003)
25. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am. J. Obstet. Gynecol. 188(6), 1383-1392 (2003)
26. Schiffman M, Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS)Arch. Pathol. Lab. Med. 127(8), 946-949 (2003) (Pubitemid 36994853)
27. Arbyn M, Martin-Hirsch P, Buntinx F, Van Ranst M, Paraskevaidis E, Dillner J. Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J. Cell. Mol. Med. 13(4), 648-659 (2009)
28. Chan BK, Melnikow J, Slee CA, Arellanes R, Sawaya GF. Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review. Am. J. Obstet. Gynecol. 200(4), 422e421-e429 (2009)
29. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24(Suppl. 3), 78-89 (2006)
30. Paraskevaidis E, Arbyn M, Sotiriadis A et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat. Rev. 30(2), 205-211 (2004) (Pubitemid 38418058)
31. Solomon D, Papillo JL, Davey DD. Statement on HPV DNA test utilization. Acta Cytol. 53(3), 247-248 (2009)
32. Dillner J, Rebolj M, Birembaut P et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337, a1754 (2008)
33. Munoz N, Bosch FX, Castellsague X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 111(2), 278-285 (2004) (Pubitemid 38924707)
34. Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev. Vaccines 8(12), 1663-1679 (2009)
35. Brown DR, Kjaer SK, Sigurdsson K et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J. Infect. Dis. 199(7), 926-935 (2009)
36. Paavonen J, Naud P, Salmeron J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374(9686), 301-314 (2009)
37. Bogaards JA, Xiridou M, Coupe VM, Meijer CJ, Wallinga J, Berkhof J. Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for 14 high-risk types of human papillomavirus. Am. J. Epidemiol. 171(7), 817-825 (2010)
38. Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int. J. Cancer 106(6), 896-904 (2003) (Pubitemid 37071668)
39. Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24(Suppl. 3), 171-177 (2006)
40. Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlee F. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: The need for a paradigm change. Arch. Med. Res. 40(6), 478-485 (2009)
41. Rogoza RM, Ferko N, Bentley J et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine 26(Suppl. 5), F46-F58 (2008)
42. Bosch FX, Castellsague X, de Sanjose S. HPV and cervical cancer: screening or vaccination? Br. J. Cancer 98(1), 15-21 (2008).
43. Kiviat NB, Hawes SE, Feng Q. Screening for cervical cancer in the era of the HPV vaccine - the urgent need for both new screening guidelines and new biomarkers. J. Natl Cancer Inst. 100(5), 290-291 (2008) (Pubitemid 351480529)
44. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 370(9590), 890-907 (2007) (Pubitemid 47371147)
45. Anttila A, Kotaniemi-Talonen L, Leinonen M et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ 340, c1804 (2010)
46. Mayrand MH, Duarte-Franco E, Rodrigues I et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357(16), 1579-1588 (2007) (Pubitemid 47598400)
47. Bulkmans NW, Berkhof J, Rozendaal L et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370(9601), 1764-1772 (2007) (Pubitemid 350137476)
48. Naucler P, Ryd W, Tornberg S et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 357(16), 1589-1597 (2007) (Pubitemid 47598401)
49. Ronco G, Giorgi-Rossi P, Carozzi F et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 11(3), 249-257 (2010)
50. Grce M, Davies P. Human papillomavirus testing for primary cervical cancer screening. Expert Rev. Mol. Diagn. 8(5), 599-605 (2008)
51. Arbyn M, Ronco G, Meijer CJ, Naucler P. Trials comparing cytology with human papillomavirus screening. Lancet Oncol. 10(10), 935-936 (2009)
52. Franco EL. Chapter 13: primary screening of cervical cancer with human papillomavirus tests. J. Natl Cancer Inst. Monogr. 31, 89-96 (2003)
53. Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119(5), 1095-1101 (2006) (Pubitemid 44116919)
54. IARC Working Group on the Evaluation of Cancer Preventive Strategies. IARC Handbooks of Cancer Prevention. Volume 10: Cervix Cancer Screening. IARC Press, Lyon, France (2005)
55. Arbyn M, Kyrgiou M, Simoens C et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: metαanalysis. BMJ 337, a1284 (2008)
56. Franco EL, Coutlee F, Ferenczy A. Integrating human papillomavirus vaccination in cervical cancer control programmes. Public Health Genomics 12(5-6), 352-361 (2009)
57. Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 26(Suppl. 1), A16-A23 (2008) (Pubitemid 351312311)
58. Leinonen M, Nieminen P, Kotaniemi- Talonen L et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J. Natl Cancer Inst. 101(23), 1612-1623 (2009)
59. Ogilvie GS, van Niekerk DJ, Krajden M et al. A randomized controlled trial of human papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL trial)BMC Cancer 10, 111 (2010)
60. Kulasingam SL, Rajan R, St Pierre Y, Atwood CV, Myers ER, Franco EL. Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis. BMC Med. 7, 69 (2009)
61. Vijayaraghavan A, Efrusy MB, Goodman KA, Santas CC, Huh WK. Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening. Gynecol. Oncol. 119(2), 237-242 (2010)
62. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16, 18 vaccination. J. Natl Cancer Inst. 100(5), 308-320 (2008) (Pubitemid 351480523)
63. Berkhof J, Coupe VM, Bogaards JA et al. The health and economic effects of HPV DNA screening in The Netherlands. Int. J. Cancer 127(9), 2147-2158 (2010)
64. Cuzick J, Szarewski A, Mesher D et al. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-results from the Hammersmith study. Int. J. Cancer 122(10), 2294-2300 (2008) (Pubitemid 351542334)
65. Kotaniemi-Talonen L, Anttila A, Malila N et al. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3 Eur. J. Cancer 44(4), 565-571 (2008)
66. Kitchener HC, Almonte M, Thomson C et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 10(7), 672-682 (2009)
67. Sankaranarayanan R, Nene BM, Dinshaw KA et al. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int. J. Cancer 116(4), 617-623 (2005) (Pubitemid 41099199)
68. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290(6), 781-789 (2003) (Pubitemid 37432955)
69. Khan MJ, Castle PE, Lorincz AT et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl Cancer Inst. 97(14), 1072-1079 (2005) (Pubitemid 41417924)
70. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol. Biomarkers Prev. 17(10), 2536-2545 (2008)
71. Cuschieri KS, Cubie HA, Whitley MW et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J. Clin. Pathol. 57(1), 68-72 (2004) (Pubitemid 38091314)
72. Monsonego J, Hudgens MG, Zerat L et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid based cytology in primary cervical cancer screening (The FASE study)Int. J. Cancer DOI: 101002/ijc.25726 (2010) (Epub ahead of print)
73. Tsoumpou I, Arbyn M, Kyrgiou M et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and metαanalysis. Cancer Treat. Rev. 35(3), 210-220 (2009)
74. Haidopoulos D, Partsinevelos GA, Vlachos GD et al. p16 INK4A is a strong biomarker for cervical intraepithelial neoplasia and invasive cervical carcinoma: a reappraisal. Reprod. Sci. 16(7), 685-693 (2009)
75. Mao C, Balasubramanian A, Yu M et al. Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study. Int. J. Cancer 120(11), 2435-2438 (2007) (Pubitemid 46642131)
76. Wentzensen N, Bergeron C, Cas F, Vinokurova S, von Knebel Doeberitz M. Triage of women with ASCUS and LSIL cytology: use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. Cancer 111(1), 58-66 (2007) (Pubitemid 46281086)
77. Denton KJ, Bergeron C, Klement P, Trunk MJ, Keller T, Ridder R. The sensitivity and specificity of p16(INK4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results. Am. J. Clin. Pathol. 134(1), 12-21 (2010)
78. Meyer JL, Hanlon DW, Andersen BT, Rasmussen OF, Bisgaard K. Evaluation of p16INK4a expression in ThinPrep cervical specimens with the CINtec p16INK4a assay: correlation with biopsy follow-up results. Cancer 111(2), 83-92 (2007) (Pubitemid 46648406)
79. Holladay EB, Logan S, Arnold J, Knesel B, Smith GD. A comparison of the clinical utility of p16(INK4a) immunolocalization with the presence of human papillomavirus by hybrid capture 2 for the detection of cervical dysplasia/neoplasia. Cancer 108(6), 451-461 (2006) (Pubitemid 46076964)
80. Carozzi F, Cecchini S, Confortini M et al. Role of P16(INK4a) expression in identifying CIN2 or more severe lesions among HPV-positive patients referred for colposcopy after abnormal cytology. Cancer 108(2), 119-123 (2006)
81. Nieh S, Chen SF, Chu TY, Lai HC, Fu E. Expression of p16INK4A in Pap smears containing atypical glandular cells from the uterine cervix. Acta Cytol. 48(2), 173-180 (2004) (Pubitemid 38381102)
82. Guo M, Hu L, Baliga M, He Z, Hughson MD. The predictive value of p16(INK4a) and hybrid capture 2 human papillomavirus testing for high-grade cervical intraepithelial neoplasia. Am. J. Clin. Pathol. 122(6), 894-901 (2004) (Pubitemid 39577357)
83. Nieh S, Chen SF, Chu TY, Lai HC, Fu E. Expression of p16 INK4A in Papanicolaou smears containing atypical squamous cells of undetermined significance from the uterine cervix. Gynecol. Oncol. 91(1), 201-208 (2003) (Pubitemid 37188612)
84. Zeng WJ, Li Y, Fei HL et al. The value of p16ink4a expression by fluorescence in situ hybridization in triage for high risk HPV positive in cervical cancer screening. Gynecol. Oncol. 120(1), 84-88 (2011)
85. Galgano MT, Castle PE, Atkins KA, Brix WK, Nassau SR, Stoler MH. Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am. J. Surg. Pathol. 34(8), 1077-1087 (2010)
86. Carozzi F, Confortini M, Dalla PP et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 9(10), 937-945 (2008)
87. Wentzensen N, von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Dis. Markers 23(4), 315-330 (2007) (Pubitemid 47015791)
88. Szarewski A, Ambroisine L, Cadman L et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol. Biomarkers Prev. 17(11), 3033-3042 (2008)
89. Cuzick J, Szarewski A, Cubie H et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362(9399), 1871-1876 (2003) (Pubitemid 37518501)
90. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J. Low Genit. Tract. Dis. 11(4), 201-222 (2007) (Pubitemid 47530909)
91. Sasieni P, Castle PE, Cuzick J. Further analysis of the ARTISTIC trial. Lancet Oncol. 10(9), 841-842 (2009)
92. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. J. Low Genit. Tract. Dis. 12(1), 1-7 (2008)
93. Howlett RI, Miller AB, Pasut G, Mai V. Defining a strategy to evaluate cervical cancer prevention and early detection in the era of HPV vaccination. Prev. Med. 48(5), 432-437 (2009)
94. Human Papillomavirus (HPV): Information about the Human Papillomavirus (HPV) Immunisation Program funded under the Immunise Australia Program.
95. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am. J. Obstet. Gynecol. 197(4), 356e351-e356 (2007)
96. Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J. Natl Cancer Inst. 92(10), 818-825 (2000) (Pubitemid 30368038)
97. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol. Biomarkers Prev. 9(9), 945-951 (2000)
98. Schiffman M, Herrero R, Hildesheim A et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 283(1), 87-93 (2000) (Pubitemid 30038388)
99. Belinson J, Qiao YL, Pretorius R et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol. Oncol. 83(2), 439-444 (2001) (Pubitemid 33033096)
100. Blumenthal PD, Gaffikin L, Chirenje ZM, McGrath J, Womack S, Shah K. Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear. Int. J. Gynaecol. Obstet. 72(1), 47-53 (2001) (Pubitemid 32007864)
101. Clavel C, Masure M, Bory JP et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br. J. Cancer 84(12), 1616-1623 (2001) (Pubitemid 32612492)
102. Belinson JL, Qiao YL, Pretorius RG et al. Shanxi Province cervical cancer screening study II: self-sampling for high-risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology. Int. J. Gynecol. Cancer 13(6), 819-826 (2003) (Pubitemid 38235227)
103. Coste J, Cochand-Priollet B, de Cremoux P et al. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. BMJ 326(7392), 733 (2003)
104. Petry KU, Menton S, Menton M et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br. J. Cancer 88(10), 1570-1577 (2003) (Pubitemid 36713784)
105. Salmeron J, Lazcano-Ponce E, Lorincz A et al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control 14(6), 505-512 (2003). (Pubitemid 36999965)
106. Sankaranarayanan R, Chatterji R, Shastri SS et al. Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in India. Int. J. Cancer 112(2), 341-347 (2004) (Pubitemid 39244376)
107. Sankaranarayanan R, Thara S, Sharma A et al. Accuracy of conventional cytology: results from a multicentre screening study in India. J. Med. Screen. 11(2), 77-84 (2004) (Pubitemid 38829884)
108. Bigras G, de Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women. Br. J. Cancer 93(5), 575-581 (2005) (Pubitemid 43080002)
109. Sarian LO, Derchain SF, Naud P et al. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin American Screening) study. J. Med. Screen. 12(3), 142-149 (2005) (Pubitemid 41337147)
110. Almonte M, Ferreccio C, Winkler JL et al. Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. Int. J. Cancer 121(4), 796-802 (2007) (Pubitemid 47106209)
111. Ronco G, Giorgi-Rossi P, Carozzi F et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J. Natl Cancer Inst. 100(7), 492-501 (2008).